Published in J Clin Invest on December 01, 1992
Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest (1996) 4.98
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest (1994) 3.49
Endothelial dysfunction in diabetes. Br J Pharmacol (2000) 3.13
Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res (2010) 2.87
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest (1994) 2.06
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
Recent developments in nitric oxide donor drugs. Br J Pharmacol (2007) 1.94
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1996) 1.86
Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J (2000) 1.63
Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest (1994) 1.53
Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation (2007) 1.47
Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart (1997) 1.38
Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest (1997) 1.22
Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal (2009) 1.14
Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol (1994) 1.06
Human endothelial dysfunction: EDRFs. Pflugers Arch (2010) 1.04
Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats. Br J Pharmacol (1994) 1.03
The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol (2014) 1.02
Diabetes-induced activation of system y+ and nitric oxide synthase in human endothelial cells: association with membrane hyperpolarization. J Physiol (1995) 1.01
Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol (2010) 0.96
Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. Br J Ophthalmol (2002) 0.95
The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest (1994) 0.94
Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. Surgery (2015) 0.93
Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Br J Pharmacol (1995) 0.92
The effects of blocking Angiotensin receptors on early stages of diabetic nephropathy. Int J Prev Med (2012) 0.92
Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol (1999) 0.92
Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart (1998) 0.91
Endothelial function evaluated by flow-mediated dilatation in pediatric vascular disease. Pediatr Cardiol (2005) 0.86
Quantitative aspects of the inhibition by N(G)-monomethyl-L-arginine of responses to endothelium-dependent vasodilators in human forearm vasculature. Br J Pharmacol (2001) 0.85
Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol (2004) 0.85
Nitric oxide 9 years on. J R Soc Med (1996) 0.85
Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Br J Pharmacol (1995) 0.84
Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hypertens (2013) 0.84
Effects of aging and type 2 diabetes on resting and post occlusive hyperemia of the forearm; the impact of rosiglitazone. BMC Endocr Disord (2005) 0.84
NG-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis. J Clin Invest (1996) 0.83
Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement. Br J Clin Pharmacol (2001) 0.83
Nitric oxide in the human cardiovascular system--SKB lecture 1997. Br J Clin Pharmacol (1998) 0.83
Alpha-linolenic acid exerts an endothelial protective effect against high glucose injury via PI3K/Akt pathway. PLoS One (2013) 0.82
Body fat and sympathetic nerve activity. Cardiovasc Drugs Ther (1996) 0.82
Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol (1995) 0.82
Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol (2009) 0.82
Red blood cell ATP/ADP & nitric oxide: The best vasodilators in diabetic patients. J Diabetes Metab Disord (2012) 0.82
Posturally induced vasoconstriction in diabetes mellitus. Arch Dis Child (1994) 0.81
Noninvasive assessment of coronary vasodilation using cardiovascular magnetic resonance in patients at high risk for coronary artery disease. J Cardiovasc Magn Reson (2008) 0.81
Elevated fibroblast growth factor-2 increases tumor necrosis factor-alpha induced endothelial cell death in high glucose. J Cell Physiol (2008) 0.80
Smoking counteracts the favorable effect of exercise training on endothelial function in patients with type 2 diabetes. Jpn Clin Med (2013) 0.79
Insulin renders diabetic rats resistant to acute ischemic stroke by arresting nitric oxide reaction with superoxide to form peroxynitrite. J Biomed Sci (2014) 0.78
Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol (1999) 0.77
Fundus pulsation measurements in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (1997) 0.77
The effect of insulin treatment and of islet transplantation on the resistance artery function in the STZ-induced diabetic rat. Br J Pharmacol (1996) 0.77
The ocular hemodynamic response to nitric oxide synthase inhibition is unaltered in patients with early type I diabetes. Graefes Arch Clin Exp Ophthalmol (2003) 0.77
Advances in diabetes for the millennium: diabetes and the endothelium. MedGenMed (2004) 0.77
Impact of Diabetes Mellitus. Arterioscler Thromb Vasc Biol (2016) 0.75
Free radicals and vascular disease. BMJ (1993) 0.75
Cell matrix contact modifies endothelial major histocompatibility complex class II expression in high-glucose environment. Am J Physiol Heart Circ Physiol (2013) 0.75
Endothelium is required in the vascular spasm induced by tetraethylammonium and endothelin-1 in guinea-pig aorta. Br J Pharmacol (1999) 0.75
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Front Pharmacol (2017) 0.75
Assessment of endothelium-mediated vasodilation of the peripheral circulation by transcutaneous ultrasonography and venous occlusion plethysmography. Heart Vessels (1999) 0.75
Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production. Aging Cell (2017) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
The measurement of volume changes in human limbs. J Physiol (1953) 9.67
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol (1987) 5.13
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol (1988) 4.16
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun (1989) 3.11
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun (1990) 2.77
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest (1990) 2.69
Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med (1989) 2.67
Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (1954) 2.56
Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol (1989) 2.44
Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet (1990) 2.04
Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn Schmiedebergs Arch Pharmacol (1989) 2.03
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
Vascular responsiveness and cation exchange in insulin-dependent diabetes. Clin Sci (Lond) (1991) 1.60
Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol (1989) 1.51
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia (1987) 1.41
Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol (1990) 1.36
Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol (1988) 1.33
Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med (1976) 1.33
The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol (1991) 1.28
Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am J Physiol (1989) 1.26
Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension. Clin Sci (Lond) (1982) 1.21
Features of endothelial dysfunction in early diabetic nephropathy. Lancet (1989) 1.20
The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol (1991) 1.18
Diabetes and hypertensive vascular disease. Mechanisms and treatment. Am J Cardiol (1973) 1.15
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol (1991) 1.12
Endothelial cell function in diabetic microangiopathy. Diabetologia (1987) 1.07
Pathobiology of endothelial and other vascular cells in diabetes mellitus. Call for data. Diabetes (1991) 0.97
Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med (1991) 0.92
A reversible vascular abnormality associated with diabetic ketosis. Clin Sci (1970) 0.81
Racial and sexual discrimination in the selection of students for London medical schools. Med Educ (1986) 12.23
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet (1992) 4.64
A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ (1999) 3.23
Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet (1997) 2.66
Simplified method for measuring compliance of superficial veins. Cardiovasc Res (1971) 2.65
What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ (2000) 2.65
Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension (1995) 2.54
Management of a restricted drugs policy in hospital: the first five years' experience. Lancet (1985) 2.54
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci U S A (1990) 2.19
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res (2001) 2.02
Vitamin B-6: food or medicine? The rules--and the politics--are different. BMJ (1998) 2.02
Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J (1999) 2.00
Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res (1989) 1.98
Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol (1999) 1.96
Enalapril-induced cough. Lancet (1986) 1.86
Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. BMJ (1990) 1.81
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmacol (1979) 1.76
Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res (1994) 1.74
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res (1999) 1.69
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol (1996) 1.68
Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation (1997) 1.61
Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol (1992) 1.51
Measurement of nitrite and nitrate levels in plasma and urine--what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens (1998) 1.51
Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation (2001) 1.49
Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res (1994) 1.43
Observations on CEREBRAL HAEMORRHAGE DUE TO CAUSES OTHER THAN ARTERIOSCLEROSIS. Br Med J (1931) 1.41
Doctors and patients should sign prescriptions. BMJ (1998) 1.40
Drug company representatives and sales priorities. Lancet (1993) 1.39
Ethics committees. Wandsworth District Research Ethics Committee. Lancet (1996) 1.39
Taking risks: primary prevention of cardiovascular events. N Z Med J (2001) 1.38
Questionnaire assessment of patients' attitudes and beliefs about asthma. Fam Pract (1986) 1.37
Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res (1993) 1.35
Predictors of mortality in hemodialysis patients. J Am Soc Nephrol (1993) 1.30
Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int (2006) 1.30
Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol (1994) 1.28
Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int (1997) 1.28
Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol (2001) 1.28
Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke (1998) 1.26
Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke (2004) 1.25
Distress and radiological investigations of the urinary tract in children. Eur J Pediatr (1996) 1.24
Nitric oxide and cardiovascular control. Exp Physiol (1993) 1.21
Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int (1994) 1.20
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics (2000) 1.20
Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology (1992) 1.18
Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci (1989) 1.17
Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. Am J Clin Pathol (1998) 1.14
The child with a non-blanching rash: how likely is meningococcal disease? Arch Dis Child (2001) 1.13
Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin Sci (Lond) (2000) 1.12
Interventions for the prevention and management of neck/upper extremity musculoskeletal conditions: a systematic review. Occup Environ Med (2006) 1.12
Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet (2001) 1.12
Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol (2008) 1.11
Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res (1996) 1.11
Biochemical characterization of S-nitrosohemoglobin. Mechanisms underlying synthesis, no release, and biological activity. J Biol Chem (1999) 1.09
Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation (2000) 1.08
Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol (1995) 1.07
Marital problems and sexual dysfunction: how are they related? Br J Psychiatry (1988) 1.07
Confusion over use of placebos in clinical trials. BMJ (1995) 1.05
Lifetime risk of developing coronary heart disease. Lancet (1999) 1.04
A survey of suicidal behaviour in the Mid-Essex area in 1972. J R Coll Physicians Lond (1976) 1.02
Nitric oxide takes centre-stage with newly defined roles. Trends Pharmacol Sci (1992) 1.01
Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet (1993) 1.01
Removal of metronidazole by haemodialysis. Br J Surg (1980) 1.00
Genetic epidemiological study of schizophrenia in Palau, Micronesia: prevalence and familiality. Am J Med Genet (1999) 1.00
Drugs and the fetus. BMJ (1996) 1.00
Effect of stress management on blood pressure in mild primary hypertension. BMJ (1993) 1.00
Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat (2001) 0.99
Drug therapy for coronary heart disease: the Sheffield table. Lancet (1998) 0.99
The reproducibility of endometrial volume acquisition and measurement with the VOCAL-imaging program. Ultrasound Obstet Gynecol (2002) 0.98
Local venous responses to endotoxin in humans. Circulation (1996) 0.98
Biology and clinical relevance of nitric oxide. BMJ (1994) 0.97
Nitric oxide and vascular responses in Type I diabetes. Diabetologia (2000) 0.97
Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol (2001) 0.97
Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol (1994) 0.96
Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. Cardiovasc Res (2000) 0.96
Periodontal therapy: a novel non-drug-induced experimental model to study human inflammation. J Periodontal Res (2004) 0.96
Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant (1996) 0.95
Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension (2001) 0.95
Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther (1995) 0.95
Nitric oxide and blood pressure: effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens (1996) 0.95
Dilator actions of arginine in human peripheral vasculature. Clin Sci (Lond) (1991) 0.93
Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Trans R Soc Trop Med Hyg (1997) 0.93
Economic evaluation alongside a phase II, multi-centre, randomised controlled trial of very early rehabilitation after stroke (AVERT). Cerebrovasc Dis (2008) 0.93
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun (2003) 0.92
Using multimedia for patient information--a program about nocturnal enuresis. Br J Urol (1998) 0.91
Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol (1999) 0.91
Injury prevention training: a cluster randomised controlled trial assessing its effect on the knowledge, attitudes, and practices of midwives and health visitors. Inj Prev (2004) 0.91